Do you want to read an article? Please log in or register.
Upadacitinib Maintenance Therapy in Pediatric Ulcerative Colitis: 52-week Multicenter Study from the Porto Group of ESPGHAN
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Real-World Experience with Upadacitinib for Pediatric Acute Severe Ulcerative Colitis: An International Multicenter Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN
Inflamm Bowel Dis
Yerushalmy-Feler A, Spencer EA, Bergstein S, Mitrova K, Hradsky O, Bramuzzo M, Wlazlo M, Olbjørn C, Rungoe C, Weil N, Turner D, Cohen S
doi: 10.1093/ibd/izaf166
RECOMMENDED
Inflammatory Bowel Disease
Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Lancet Gastroenterol Hepatol
ACCURE Study Group
doi: 10.1016/S2468-1253(25)00026-3
Inflammatory Bowel Disease
Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Lancet Gastroenterol Hepatol
Wu K, Zheng C, Cao Q, Ding Y, Gao X, Zhong J, Chiu CT, Zhang H, Wang X, Wang B, Liang J, Liu X, Zhou Y, Xu B, Kim TO, Shen X, Chen D, Chen W, Liu Y, Shen J, Liu F, Ding X, Zhan Q, Chou JW, Zeng S, Lin Y, Ying L, Chen X, ENLIGHT UC Study Group
doi: 10.1016/S2468-1253(25)00198-0
Inflammatory Bowel Disease
Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study
Lancet Gastroenterol Hepatol
Visser E, Reijntjes MA, Heuthorst L, Stellingwerf ME, West R, van Dongen K, Crolla RMPH, van Dieren S, van der Bilt JDW, Bemelman WA, D'Haens GR, Buskens CJ, COSTA Study Group
doi: 10.1016/S2468-1253(25)00291-2
Inflammatory Bowel Disease
Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: 2-Year Results from the U-ENDURE Long-Term Extension Study
J Crohns Colitis
Loftus EV Jr, D'Haens G, Louis E, Regueiro M, Jairath V, Magro F, Nakase H, Dubcenco E, Lacerda AP, Ford S, Feng T, Duncan B, Fish I, Cunneen C, Anyanwu SI, Aponte F, Griffith J, Blumenstein I
doi: 10.1093/ecco-jcc/jjaf138
Inflammatory Bowel Disease
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study
Lancet Gastroenterol Hepatol
Panaccione R, Vermeire S, Danese S, Higgins PDR, Lichtenstein GR, Nakase H, Glover S, Colombel JF, Eccleston J, Kujawski M, Remple V, Yao X, Geng Z, Palac H, Sharma D, Suravaram S, Schreiber S
doi: 10.1016/S2468-1253(25)00017-2
Inflammatory Bowel Disease
Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study
J Crohns Colitis
Bokemeyer B, Plachta-Danielzik S, Gilman E, Howaldt S, Mohl W, Efken P, Ehehalt R, Kahl M, Krause T, Trentmann L, Lügering A, Schnoy E, Jochum C, Hartmann P, Schreiber S
doi: 10.1093/ecco-jcc/jjaf052
Inflammatory Bowel Disease
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)
J Crohns Colitis
Colombel JF, Sandborn WJ, Schreiber S, Danese S, Kłopocka M, Kierkuś J, Kulynych R, Gonciarz M, Sołtysiak A, Smoliński P, Srećković S, Valuyskikh E, Lahat A, Horyński M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Kim JM, Park G, Lee J, Lee J, Ryu JY, Sands BE, Hanauer SB
doi: 10.1093/ecco-jcc/jjaf060
Inflammatory Bowel Disease
Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study
Clin Gastroenterol Hepatol
Panaccione R, Regueiro M, Lee SD, Atreya R, Pedersen G, Broide E, Rodriguez C, van Bodegraven AA, Dubcenco E, Lacerda AP, Feng T, Geng Z, Wang T, van Haaren S, Anyanwu SI, Panés J
doi: 10.1016/j.cgh.2025.07.028